Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition;Avances en la prevención y el tratamiento de las metástasis óseas en cáncer de próstata. Papel de la inhibición de RANK/RANKL

Actas Urologicas Espanolas

Volumn 37, Issue 5, 2013, Pages 292-304

  Gomez Veiga, F ^a   Ponce Reixa, J ^a   Martinez Breijo, S ^a   Planas, J ^b   Morote, J ^b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bone metastases; Denosumab; Prostate cancer; RANK; RANKL; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR PROTEIN; ZOLEDRONIC ACID;

ADENOCARCINOMA; ARTICLE; BIOLOGICAL MODEL; BONE TUMOR; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FORECASTING; HUMAN; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATHOLOGIC FRACTURE; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FORECASTING; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84876920450     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2012.09.001     Document Type: Short Survey

References (78)

1. Cancer Incidence, mortality and prevalence worldwide in 2008. Globocan 2008 [consultado 29 Dic 2011]. Disponible en: http://globocan.iarc.fr/
2. D.A. Loblaw, K.S. Virgo, R. Nam, M.R. Somerfield, E. Ben-Josef, and D.S. Mendelson Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605 (Pubitemid 46733088)
3. J. Morote, and J. Planas Pérdida de masa ósea en pacientes con cáncer de próstata sometidos a deprivación androgénica Actas Urol Esp 35 2011 232 239
4. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
5. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
6. J.S. De Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, and L. Chu Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
7. J.S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, and I. Kocak Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
8. J.T. Buijs, and G. van der Pluijm Osteotropic cancers: from primary tumor to bone Cancer Lett 273 2009 177 193
9. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 20 Pt 2 2006 6243s 6249s (Pubitemid 44703797)
10. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
11. D.D. Coward, and D.J. Wilkie Metastatic bone pain. Meanings associated with self-report and self-management decision making Cancer Nurs 23 2000 101 108
12. K.P. Weinfurt, Y. Li, L.D. Castel, F. Saad, J.W. Timbie, and G.A. Glendenning The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 2005 579 584 (Pubitemid 40613323)
13. V. DePuy, K.J. Anstrom, L.D. Castel, K.A. Schulman, K.P. Weinfurt, and F. Saad Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer Support Care Cancer 15 2007 869 876 (Pubitemid 47387507)
14. K.P. Weinfurt, L.D. Castel, Y. Li, J.W. Timbie, G.A. Glendenning, and K.A. Schulman Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions Med Care 42 2004 164 175
15. C. Clare, D. Royle, K. Saharia, H. Pearse, S. Oxberry, and K. Oakley Painful bone metastases: a prospective observational cohort study Palliat Med 19 2005 521 525 (Pubitemid 41645510)
16. L. Costa, and P.P. Major Effect of bisphosphonates on pain and quality of life in patients with bone metastases Nat Clin Pract Oncol 6 2009 163 174
17. N.A. Janjan, R. Payne, T. Gillis, D. Podoloff, H.I. Libshitz, and R. Lenzi Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases J Pain Symptom Manage 16 1998 171 178 (Pubitemid 28429065)
18. M. Di Maio, C. Gridelli, C. Gallo, L. Manzione, L. Brancaccio, and S. Barbera Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer Br J Cancer 90 2004 2288 2296 (Pubitemid 38961890)
19. H.X. Jiang, S.R. Majumdar, D.A. Dick, M. Moreau, J. Raso, and D.D. Otto Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures J Bone Miner Res 20 2005 494 500 (Pubitemid 40297910)
20. J.J. Roche, R.T. Wenn, O. Sahota, and C.G. Moran Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study BMJ 331 2005 1374
21. K.L. Schulman, and J. Kohles Economic burden of metastatic bone disease in the U.S. Cancer 109 2007 2334 2342 (Pubitemid 46801565)
22. K. Kennedy, and H. Patel Update on the pharmacological prevention of skeletal-related events in cancer patients Orthopedics 34 2011 982 985
23. J.E. Brown, H. Neville-Webbe, and R.E. Coleman The role of bisphosphonates in breast and prostate cancers Endocr Relat Cancer 11 2004 207 224 (Pubitemid 38832826)
24. M.T. Drake, B.L. Clarke, and S. Khosla Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 2008 1032 1045
25. P. Clezardin, F.H. Ebetino, and P.G. Fournier Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity Cancer Res 65 2005 4971 4974 (Pubitemid 40827299)
26. T.A. Guise Antitumor effects of bisphosphonates: promising preclinical evidence Cancer Treat Rev 34 2008 S19 S24
27. R. Montague, C.A. Hart, N.J. George, V.A. Ramani, M.D. Brown, and N.W. Clarke Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer Eur Urol 46 2004 389 401
28. T. Tanaka, H. Kawashima, K. Ohnishi, K. Matsumura, R. Yoshimura, and M. Matsuyama Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells Anticancer Res 29 2009 1089 1094
29. A. Ullen, L. Lennartsson, U. Harmenberg, M. Hjelm-Eriksson, K.M. Kalkner, and B. Lennernas Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid Acta Oncol 44 2005 644 650 (Pubitemid 41503612)
30. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
31. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
32. J.M. Cozar, J. Carballido, P. Luque, A. Tabernero, A. Barreiro, and E. Sánchez Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis Patient Prefer Adherence 2 2008 215 224
33. A. Heidenreich, R. Hofmann, and U.H. Engelmann The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer J Urol 165 2001 136 140
34. A. Heidenreich, A. Elert, and R. Hofmann Ibandronate in the treatment of prostate cancer associated painful osseous metastases Prostate Cancer Prostatic Dis 5 2002 231 235
35. NCCN Guidelines in Oncology. Prostate Cancer. Version 4.2011. National Comprehensive Cancer Network, 2011 [consultado 30 Jan 2012]. Disponible en: www.nccn.org
36. A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M.D. Mason, and V. Matveev Guía de la EAU sobre el cáncer de próstatprostate. Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado Actas Urol Esp 35 2011 501 514
37. ZOMETA: ficha técnica [consultado 30 Jan 2012]; Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/ human/000336/WC500051730.pdf
38. I.J. Diel, I. Fogelman, B. Al-Nawas, B. Hoffmeister, C. Migliorati, and J. Gligorov Pathophysiology, risk factors and management of bisphosphonate- associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64 2007 198 207 (Pubitemid 350030960)
39. G.A. Rodan, and T.J. Martin Role of osteoblasts in hormonal control of bone resorption - a hypothesis Calcif Tissue Int 33 1981 349 351 (Pubitemid 12249943)
40. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, and R. Luthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319 (Pubitemid 27199902)
41. E. Tsuda, M. Goto, S. Mochizuki, K. Yano, F. Kobayashi, and T. Morinaga Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis Biochem Biophys Res Commun 234 1997 137 142 (Pubitemid 27267548)
42. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, and E.R. Roux A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 1997 175 179 (Pubitemid 27507987)
43. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, and C. Capparelli OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
44. K. Matsuzaki, N. Udagawa, N. Takahashi, K. Yamaguchi, H. Yasuda, and N. Shima Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures Biochem Biophys Res Commun 246 1998 199 204 (Pubitemid 28413951)
45. T.L. Burgess, Y. Qian, S. Kaufman, B.D. Ring, G. Van, and C. Capparelli The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 1999 527 538 (Pubitemid 29215717)
46. D.L. Lacey, H.L. Tan, J. Lu, S. Kaufman, G. Van, and W. Qiu Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 2000 435 448 (Pubitemid 30626907)
47. R.W. Cowan, G. Singh, and M. Ghert PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone J Orthop Res 2011
48. L.C. Hofbauer, S. Khosla, C.R. Dunstan, D.L. Lacey, W.J. Boyle, and B.L. Riggs The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J Bone Miner Res 15 2000 2 12 (Pubitemid 30026926)
49. T. Wada, T. Nakashima, N. Hiroshi, and J.M. Penninger RANKL-RANK signaling in osteoclastogenesis and bone disease Trends Mol Med 12 2006 17 25 (Pubitemid 43089652)
50. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, and T.J. Martin Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 1999 4451 4458 (Pubitemid 30666108)
51. E. Gonzalez-Suarez, A.P. Jacob, J. Jones, R. Miller, M.P. Roudier-Meyer, and R. Erwert RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis Nature 468 2010 103 107
52. D. Schramek, A. Leibbrandt, V. Sigl, L. Kenner, J.A. Pospisilik, and H.J. Lee Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer Nature 468 2010 98 102
53. E. Gonzalez-Suarez RANKL inhibition: a promising novel strategy for breast cancer treatment Clin Transl Oncol 13 2011 222 228
54. Prolia: EPAR - Public assessment report [consultado 24 Oct 2011]. Disponible en: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/001120/WC500093529.pdf
55. K. Fizazi, M. Carducci, M. Smith, R. Damiao, J. Brown, and L. Karsh Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
56. J. Brown, C. Cleeland, L. Fallowfield, D. Patrick, K. Fizazi, and M. Smith Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: results from a phase 3 trial of denosumab vs. zoledronic acid Eur Urol Suppl 10 2011 336 340
57. K. Fizazi, A. Lipton, X. Mariette, J.J. Body, Y. Rahim, and J.R. Gralow Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 2009 1564 1571
58. A.T. Stopeck, A. Lipton, J.J. Body, G.G. Steger, K. Tonkin, and R.H. de Boer Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
59. D.H. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, and J. Prausova Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
60. XGEVA: Prescribing information [consultado 30 Jan 2012]. Disponible en: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125320s007lbl.pdf
61. M.A. Climent, J.M. Piulats, A. Sánchez-Hernández, J.A. Arranz, J. Cassinello, and J. García-Donas Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Crit Rev Oncol Hematol 83 2012 341 352 10.1016/j.critrevonc.2012.01.002
62. A. Lipton Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone Cancer Treat Rev 34 Suppl. 1 2008 S25 S30
63. M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, and B. Tombal Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2011 39 46
64. M.R. Smith, F. Saad, N.D. Shore, S. Oudard, K. Miller, and B. Tombal Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics J Clin Oncol 30 2012 4510
65. C. Parker, D. Heinrich, J.M. O'Sullivan, S.D. Fossa, A. Chodacki, and T. Demkow Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases J Clin Oncol 30 2012 LBA4512
66. A. Bagnato, and P.G. Natali Endothelin receptors as novel targets in tumor therapy J Transl Med 2 2004 16
67. C.J. Weydert, A.K. Esser, R.A. Mejia, J.M. Drake, J.M. Barnes, and M.D. Henry Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles Cancer Biol Ther 8 2009 720 729
68. M.A. Carducci, F. Saad, P.A. Abrahamsson, D.P. Dearnaley, C.C. Schulman, and S.A. North A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110 2007 1959 1966 (Pubitemid 350036854)
69. J.B. Nelson, K. Fizazi, K. Miller, C.S. Higano, J.W. Moul, and T. Morris Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC) J Clin Oncol 29 2011 117
70. W.K. Kelly, S. Halabi, M. Carducci, D. George, J.F. Mahoney, and W.M. Stadler Randomized, double-blind. placebo-controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 2012 1534 1540
71. ® (aflibercept) 2012. Nota de prensa [consultado 31 May 2012]. Disponible en: http://investor.regeneron.com/ releasedetail.cfm?releaseid=661995
72. H. Beltran, T.M. Beer, M.A. Carducci, J. de Bono, M. Gleave, and M. Hussain New therapies for castration-resistant prostate cancer: efficacy and safety Eur Urol 60 2011 279 290
73. JEVTANA: ficha técnica [consultado 30 Jan 2012]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/ human/002018/WC500104764.pdf
74. ZYTIGA: ficha técnica [consultado 30 Jan 2012]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/ human/002321/WC500112858.pdf
75. ® (sipuleucel-T). Prescribing information [consultado 30 Jan 2012]. Disponible en: http://www.fda.gov/downloads/ BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031. pdf
76. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, and K. Miller Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study J Clin Oncol 30 2012 LBA1
77. XGEVA: ficha técnica [consultado 30 Jan 2012]. Disponible en: < http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002173/WC500110381.pdf >
78. J.B. Nelson, W. Love, J.L. Chin, F. Saad, C.C. Schulman, and D.J. Sleep Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 2008 2478 2487